SIETES :: 92261 citas

Resultados de la búsqueda por HEPATOLOGÍA REFINAR BÚSQUEDA

1.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

2.

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

3.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

4.

Anónimo. EMA committee calls for flupirtine to be taken off the market. DIA Daily 2018:7. [Ref.ID 102454]

5.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

6.

Anónimo. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio: actualización de la información. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 102152]

7.

Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024. [Ref.ID 102147]

8.

Anónimo. FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. FDA U.S. Food and Drug Administration 2017:21 de septiembre. [Ref.ID 102061]

9.

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]

10.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

11.

Anónimo. EMA’s PARC recommends modified-release paracetamol be removed from market. DIA Daily 2017:2. [Ref.ID 102044]

12.

Vliegenthart ADB, Berends C, Potter CMJ, Kersaudy-Kerhoas M, Dear JW. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol 2017;83:2027-33. [Ref.ID 102028]

13.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

14.

Anónimo. FDA approves HCV drug for patients who fail to respond to prior treatments that inhibit NS5A. DIA Daily 2017:1. [Ref.ID 101910]

15.

Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]

16.

Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]

17.

Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]

18.

Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet 2017;389:1880-1. [Ref.ID 101601]

19.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

20.

Anónimo. Antiviraux à action directe: interaction avec les antivitamine K. Prescrire 2017;37:262. [Ref.ID 101533]